Regen Biopharma Inc., of San Diego, said its researchers have identified a series of small-molecule drugs that inhibit NR2F6 and also activate human immune cells ex vivo. Evidence provided by studies suggest that NR2F6 represses the body's immune response against tumors, and inhibiting NR2F6 may lead to enhanced immune response against cancerous tumor cells, the company said, and – although preliminary – the findings are encouraging, since the antagonists are behaving as Regen hoped and expected.